Treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral & non?vertebral fractures and to increase bone mineral density.
Treatment of osteoporosis in men.
Treatment of Paget?s disease of bone.
Treatment and prevention of glucocorticoid?induced osteoporosis.
Prevention of clinical fractures in patients after hip fracture.
Prevention of postmenopausal osteoporosis.
Bisoprolol Fumarate+ Hydrochlorothiazide
(in injection form)
Bisoprolol is a beta1 selective (cardio selective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range.
Hydrochlorothiazide is a diuretic (benzothiadiazine) affecting the distal renal tubular mechanism increase excretion of sodium and chloride and resulting reduced blood volume or Cardiac output.
Individually Bisoprolol Fumarate and Hydrochlorothiazide used as antihypertensive agent and combination of these two drugs brings maximum response in treatment of hypertension. Hydrochlorothiazide significantly increases the antihypertensive effect of Bisoprolol Fumarate. The incidence of hypokalemia is less due to low dose of Hydrochlorothiazide.
Manufacturer: Square Pharmaceuticals Ltd.